Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company
a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The a16z Show →
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Andreessen Horowitz's Vijay Pande: "AI doctors"
🔬Beyond AlphaFold: How Boltz is Open-Sourcing the Future of Drug Discovery
Power Ranking the Big AI Ideas for 2026
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.